- Conditions
- Smoking Cessation
- Interventions
- Quitline Treatment (QT), App-based Treatment (mHealth)
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Gainesville, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 9,162
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovulation Suppression
- Interventions
- levonorgestrel and ethinyl estradiol
- Drug
- Lead sponsor
- Agile Therapeutics
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
- Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- Avacopan, Placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 56 more
- Conditions
- Coronary Artery Disease
- Interventions
- pexelizumab in conjunction with CABG
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 129 more
- Conditions
- Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
- Interventions
- Alisertib, Pralatrexate, Gemcitabine, Romidepsin
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more
- Conditions
- Schizophrenia
- Interventions
- talnetant, risperidone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
- Conditions
- Acne Vulgaris
- Interventions
- CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 15
- States / cities
- Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- Next Generation Extended Wear Sensors
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Chula Vista, California • Escondido, California • Palo Alto, California + 15 more
- Conditions
- Localized Non-Resectable Adult Liver Carcinoma
- Interventions
- Yttrium-90 Resin Microspheres
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- CRS-207, Pembrolizumab
- Biological
- Lead sponsor
- Aduro Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Sciatica
- Interventions
- REGN475, Placebo Injection
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 27 more
- Conditions
- Renal Transplantation
- Interventions
- TCD601, belatacept, ATG, TAC, MPA, Corticosteroids
- Biological · Drug
- Lead sponsor
- ITB-Med LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 18
- States / cities
- Sacramento, California • San Francisco, California • Tampa, Florida + 15 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Faricimab, Sham Procedure, Anti-VEGF Therapy
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,036 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 85
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
- Conditions
- Fistulizing Crohn's Disease
- Interventions
- Filgotinib, Placebo to match filgotinib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Miami, Florida • Orlando, Florida • Tampa, Florida + 10 more
- Conditions
- Bipolar Disorder, Manic
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 15 more
- Conditions
- Urinary Urge Incontinence
- Interventions
- Revi System Treatment, Revi System - Delayed Activation
- Device
- Lead sponsor
- BlueWind Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Pasadena, California • Riverside, California + 16 more
- Conditions
- Ovarian Cancer
- Interventions
- OTL38, near infrared camera imaging system, laparotomy
- Drug · Device · Procedure
- Lead sponsor
- On Target Laboratories, LLC
- Industry
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 7 more
- Conditions
- Diabetes type1
- Interventions
- AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
- Biological · Drug
- Lead sponsor
- Precigen Actobio T1D, LLC
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
- Conditions
- Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
- Interventions
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Escondido, California • Santa Barbara, California • Torrance, California + 10 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 64 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Sun City, Arizona • San Diego, California • Loxahatchee Groves, Florida + 10 more
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Interventions
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
- Conditions
- Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
- Interventions
- OnabotulinumtoxinA 100 UNT
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida
- Conditions
- Influenza
- Interventions
- CR8020, CR6261, Placebo
- Biological
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 21
- States / cities
- Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more